寶鋼股份(600019.SH):寶武碳業擬與萬華化學設寶萬碳纖維 以運營紹興柯橋原絲項目
格隆匯3月3日丨寶鋼股份(600019.SH)公佈,公司第八屆董事會第十次會議決議,批准《關於寶武碳業成立控股子公司開展“紹興柯橋原絲項目”的議案》。
寶武碳業科技股份有限公司(“寶武碳業”)與萬華化學集團股份有限公司合資設立“浙江寶萬碳纖維有限公司”(擬用名,最終以工商登記為準,“寶萬碳纖維”)以運營“紹興柯橋原絲項目”。寶萬碳纖維註冊資本8.5億元,全部為現金出資,其中寶武碳業出資4.335億元,持股51%;“紹興柯橋原絲項目”一期報批總投資162579萬元(不含税)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.